Publication

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.

Authors not recorded

J Clin Oncol2018PMID 29320312stubpubmedPublished

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (37)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 37

cancerBladder Carcinomacivic_curation1.00
cancerLaryngeal Squamous Cell Carcinomacivic_curation1.00
cancerLung Non-Small Cell Carcinomacivic_curation1.00
cancerMalignant Biliary Tract Neoplasmcivic_curation1.00
cancerMalignant Colorectal Neoplasmcivic_curation1.00
cancerMalignant Neoplasmcivic_curation1.00
cancerMalignant Ovarian Neoplasmcivic_curation1.00
cancerMalignant Pancreatic Neoplasmcivic_curation1.00
cancerMalignant Uterine Neoplasmcivic_curation1.00
cancerSalivary Gland Carcinomacivic_curation1.00
cancerThyroid Gland Anaplastic Carcinomacivic_curation1.00
drugPertuzumabcivic_curation1.00
drugTrastuzumabcivic_curation1.00
drugVemurafenibcivic_curation1.00
drugVismodegibcivic_curation1.00
geneBRAFcivic_curation1.00
geneERBB2civic_curation1.00
genePTCH1civic_curation1.00
geneSMOcivic_curation1.00
variantBRAF Fusioncivic_curation1.00
variantBRAF Fusioncivic_curation1.00
variantBRAF G464Vcivic_curation1.00
variantBRAF G466Vcivic_curation1.00
variantBRAF G469Acivic_curation1.00
variantBRAF G496Acivic_curation1.00
variantBRAF G596Rcivic_curation1.00
variantBRAF G606Ecivic_curation1.00
variantBRAF intron 10 rearrangementcivic_curation1.00
variantBRAF intron 9 rearrangementcivic_curation1.00
variantBRAF L597Qcivic_curation1.00
variantBRAF N581Scivic_curation1.00
variantBRAF P731Tcivic_curation1.00
variantBRAF V600Ecivic_curation1.00
variantERBB2 Amplificationcivic_curation1.00
variantERBB2 Mutationcivic_curation1.00
variantPTCH1 Mutationcivic_curation1.00
variantSMO Mutationcivic_curation1.00

Curated evidence

Evidence citing this paper (29)

civicCuratedShowing 1–29 of 29 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ERBB2 Amplification6
Pertuzumab + TrastuzumabCombination	Bladder Carcinoma	Predictive	B	Supports Sensitivity Response	3	accepted	EID5982 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Three of nin… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
〃	Malignant Biliary Tract NeoplasmALIAS	Predictive	B	Supports Sensitivity Response	2	accepted	EID5983 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Two of seven… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
Pertuzumab + TrastuzumabCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	accepted	EID5981 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Thirty of 1… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
Pertuzumab + TrastuzumabCombination	Malignant Pancreatic Neoplasm	Predictive	B	Supports Sensitivity Response	2	accepted	EID5985 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Two of nine … (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
〃	Malignant Uterine NeoplasmALIAS	Predictive	B	Does Not Support Sensitivity Response	2	accepted	EID5986 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. None of the … (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
〃	Salivary Gland Carcinoma	Predictive	B	Supports Sensitivity Response	2	accepted	EID5984 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Four of five… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
BRAF V600E5
Vemurafenib	Laryngeal Squamous Cell Carcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID5962 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. One patient … (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	accepted	EID5958 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Within the B… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
〃	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Sensitivity Response	2	accepted	EID5960 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Among 2 pati… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
〃	Malignant Ovarian Neoplasm	Predictive	B	Supports Sensitivity Response	3	accepted	EID5959 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Among 4 pati… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
Pertuzumab + VemurafenibCombination	Thyroid Gland Anaplastic CarcinomaALIAS	Predictive	C	Supports Sensitivity Response	3	accepted	EID5961 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. One patient … (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
ERBB2 Mutation1
Pertuzumab + TrastuzumabCombination	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	2	accepted	EID5980 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Among thirty… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
BRAF G464V1
Vemurafenib	Malignant NeoplasmALIAS	Predictive	C	Does Not Support Sensitivity Response	2	accepted	EID5964 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patien… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
BRAF G466V1
Vemurafenib	Malignant NeoplasmALIAS	Predictive	C	Does Not Support Sensitivity Response	2	accepted	EID5968 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patien… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
BRAF G469A1
Vemurafenib	Malignant NeoplasmALIAS	Predictive	C	Does Not Support Sensitivity Response	2	accepted	EID5965 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patien… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
BRAF G496A1
Vemurafenib	Malignant NeoplasmALIAS	Predictive	C	Does Not Support Sensitivity Response	2	accepted	EID5966 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patien… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
BRAF G596R1
Vemurafenib	Malignant NeoplasmALIAS	Predictive	C	Does Not Support Sensitivity Response	2	accepted	EID5969 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patien… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
BRAF G606E1
Vemurafenib	Malignant NeoplasmALIAS	Predictive	C	Does Not Support Sensitivity Response	2	accepted	EID5970 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patien… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
BRAF intron 10 rearrangement1
Vemurafenib	Malignant NeoplasmALIAS	Predictive	C	Does Not Support Sensitivity Response	2	accepted	EID5974 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively Of 26 patient… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
BRAF intron 9 rearrangement1
Vemurafenib	Malignant NeoplasmALIAS	Predictive	C	Does Not Support Sensitivity Response	2	accepted	EID5973 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patien… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
BRAF K601E1
Vemurafenib	Malignant NeoplasmALIAS	Predictive	B	Does Not Support Sensitivity Response	3	submitted	EID5963 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patien… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
BRAF L597Q1
Vemurafenib	Malignant NeoplasmALIAS	Predictive	C	Does Not Support Sensitivity Response	2	accepted	EID5971 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patien… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
BRAF N581S1
Vemurafenib	Malignant NeoplasmALIAS	Predictive	C	Does Not Support Sensitivity Response	2	accepted	EID5967 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patien… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
BRAF P731T1
Vemurafenib	Malignant NeoplasmALIAS	Predictive	C	Does Not Support Sensitivity Response	2	accepted	EID5972 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patien… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
BRAF WASFL::BRAF1
Vemurafenib	Malignant NeoplasmALIAS	Predictive	C	Does Not Support Sensitivity Response	2	rejected	EID5976 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patien… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
BRAF Fusion1
Vemurafenib	Malignant NeoplasmALIAS	Predictive	C	Does Not Support Sensitivity Response	2	accepted	EID5975 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively Of 26 patient… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
PTCH1 Mutation1
Vismodegib	Malignant NeoplasmALIAS	Predictive	B	Supports Sensitivity Response	1	accepted	EID5978 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Twenty-one p… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
SMO Mutation1
Vismodegib	Malignant NeoplasmALIAS	Predictive	B	Does Not Support Sensitivity Response	2	accepted	EID5979 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Twenty-one p… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
BRAF Fusion1
Vemurafenib	Malignant Pancreatic Neoplasm	Predictive	C	Supports Sensitivity Response	2	accepted	EID5977 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. One of 23 pa… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic